|
|
|
|
| LEADER |
01768nam a2200361 u 4500 |
| 001 |
EB001872267 |
| 003 |
EBX01000000000000001035638 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
190824 r ||| eng |
| 245 |
0 |
0 |
|a CADTH Canadian Drug Expert Committee recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.)
|h Elektronische Ressource
|b indication : adult patients with active psoriatic arthritis (PsA) who have responded inadequately to, or are intolerant to one or more disease-modifying antirheumatic drugs (DMARD)
|
| 246 |
3 |
1 |
|a Drug reimbursement recommendation Ixekizumab (Taltz)
|
| 246 |
3 |
1 |
|a Ixekizumab (Taltz -- Eli Lilly Canada Inc.)
|
| 250 |
|
|
|a Version 1.0
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2018, August 2018
|
| 300 |
|
|
|a 1 PDF file (8 pages)
|
| 653 |
|
|
|a Insurance, Health, Reimbursement
|
| 653 |
|
|
|a Antirheumatic Agents / therapeutic use
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Arthritis, Psoriatic / drug therapy
|
| 653 |
|
|
|a Dermatologic Agents / economics
|
| 710 |
2 |
|
|a CADTH Canadian Drug Expert Committee
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 500 |
|
|
|a "Final"
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK539325
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 700
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 330
|
| 520 |
|
|
|a The CADTH Canadian Drug Expert Committee (CDEC) recommends that ixekizumab be reimbursed for the treatment of adult patients with active PsA who have responded inadequately to, or are intolerant to one or more DMARD.
|